An article published Online First and in an upcoming edition of The Lancet Oncology reports that an oral bisphosphonate, sodium clodronate, improves overall survival in men with advanced prostate cancer. However, it does not reduce the risk of death in men with localized disease. These are the final results of the MRC PR05 and MRC [...]
Just revealed in briefing documents which were released in advance of a scheduled Thursday meeting of the FDA’s Advisory Committee for Reproductive Health Drugs, which will be considering whether to recommend denosumab for approval, are significant concerns that denosumab, the investigational biologic drug for osteoporosis, may increase risk of serious infections through its activity against [...]
— A New Trial Marks Expanded Phase 3 Development of MDV3100 into Earlier-Stage Disease — Medivation, Inc. and Astellas Pharma Inc. today announced the launch of a second Phase 3 clinical trial of their investigational drug MDV3100. This trial marks the expansion of the Phase 3 development of their novel, triple-acting oral androgen receptor antagonist [...]
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced the publication of results from their randomized Phase 2 trial of custirsen for men with advanced prostate cancer in the September 20, 2010 Journal of Clinical Oncology. According to their announcement, the trial results showed a survival benefit with their investigational agent OGX-011/TV1011 (custirsen) in men with advanced prostate [...]
Ortho Biotech & Development, a unit of Cougar Biotechnology, Inc. has unblinded their Phase 3 study of abiraterone acetate plus prednisone. In the trial the abiraterone was used for the treatment of men with metastatic advanced prostate cancer has progressed following treatment with one or two chemotherapy regimens at least one of which contained docetaxel. [...]
In men with prostate cancer hot flashes are one of the most commonly reported adverse effects of hormonal therapy (ADT). Researchers at the Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon wanted to confirm the many reports that acupuncture can moderate hot flashes. […]
Biochemical recurrence of prostate cancer after primary therapy (PSA only) remains a significant problem. Deciding on the best treatment options for men who have failed primary therapy without documented evidence of metastatic disease remains limited and controversial. Androgen deprivation therapy (ADT), the usual next step for biochemical recurrence does prolong the time to further disease [...]
Findings from the Prostate, Lung, Colorectal and Ovarian (PLCO) screening trial indicate that the strongest predictors of prostate cancer-specific mortality include Gleason 7, body mass index >30, African-American race, PSA level, stage, and high co-morbidity score. Understanding how non-tumor factors affect prostate cancer-specific mortality will help identify those men who may benefit from screening and [...]
The use of high-intensity focused ultrasound (HIFU) for the primary treatment of prostate cancer will probably become more common in the very near future. HIFU has been used for many years in Europe and Mexico and has recently been in clinical trials in the United States. HIFU has been a successful method of prostate cancer [...]
Dr. Yang-Min Ning and collaborators reported, in the April 20, 2010 issue of the Journal of Clinical Oncology, a Phase II trial which combined chemotherapy (docetaxel) with an anti-angiogenesis drug for men with castration-resistant prostate cancer (CRPC). The data suggests that such a combination is more effective than chemotherapy alone. […]
